110 related articles for article (PubMed ID: 28219876)
1. [Recurrence and survival analysis of postoperative patients aged 25 to 59 years with differentiated thyroid carcinoma].
Shao LC; Jian HJ; Chen GH; Liang YY; Huang WZ
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Feb; 37(2):274-277. PubMed ID: 28219876
[TBL] [Abstract][Full Text] [Related]
2. [Poorly differentiated thyroid follicular carcinoma - a clinical analysis of 30 cases].
Liu WS; Qi YF; Tang PZ
Ai Zheng; 2004 Sep; 23(9):1081-4. PubMed ID: 15363207
[TBL] [Abstract][Full Text] [Related]
3. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
4. Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure.
Wang LY; Ghossein R; Palmer FL; Nixon IJ; Tuttle RM; Shaha AR; Shah JP; Patel SG; Ganly I
Thyroid; 2015 Sep; 25(9):993-8. PubMed ID: 26122000
[TBL] [Abstract][Full Text] [Related]
5. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Mazzaferri EL; Jhiang SM
Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
7. Recurrence factors and prevention of complications of pediatric differentiated thyroid cancer.
Wang C; Chen X; Wei X; Chen F; Wang Y; Shen Z
Asian J Surg; 2017 Jan; 40(1):55-60. PubMed ID: 27697309
[TBL] [Abstract][Full Text] [Related]
8. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
9. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
10. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
11. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
12. Death from thyroid cancer of follicular cell origin.
Wu HS; Young MT; Ituarte PH; D'Avanzo A; Duh QY; Greenspan FS; Loh KC; Clark OH
J Am Coll Surg; 2000 Dec; 191(6):600-6. PubMed ID: 11129807
[TBL] [Abstract][Full Text] [Related]
13. Survival of differentiated thyroid carcinoma studied in 500 patients.
Lerch H; Schober O; Kuwert T; Saur HB
J Clin Oncol; 1997 May; 15(5):2067-75. PubMed ID: 9164219
[TBL] [Abstract][Full Text] [Related]
14. Excellent Prognosis of Central Lymph Node Recurrence-Free Survival for cN0M0 Papillary Thyroid Carcinoma Patients Who Underwent Routine Prophylactic Central Node Dissection.
Ito Y; Miyauchi A; Masuoka H; Fukushima M; Kihara M; Miya A
World J Surg; 2018 Aug; 42(8):2462-2468. PubMed ID: 29372373
[TBL] [Abstract][Full Text] [Related]
15. Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy.
Choi JB; Lee SG; Kim MJ; Kim TH; Ban EJ; Lee CR; Lee J; Kang SW; Jeong JJ; Nam KH; Chung WY; Park CS
Head Neck; 2019 Jan; 41(1):56-63. PubMed ID: 30536465
[TBL] [Abstract][Full Text] [Related]
16. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
Gemsenjäger E; Heitz PU; Martina B; Schweizer I
Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
[TBL] [Abstract][Full Text] [Related]
17. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
18. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
[TBL] [Abstract][Full Text] [Related]
20. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
